Effect of resveratrol on scopolamine-induced cognitive impairment in mice

Pharmacological Reports

Volumn 64, Issue 2, 2012, Pages 438-444

  Gupta, Rachna ^a   Gupta, Lalit K ^b   Mediratta, Pramod K ^a   Bhattacharya, Swapan K ^a  

^a UNIVERSITY COLLEGE OF MEDICAL SCIENCES   (India)

^b LADY HARDINGE MEDICAL COLLEGE   (India)

Author keywords

Cognition; Escape latency; Resveratrol; Scopolamine; Step down latency; Transfer latency

Indexed keywords

RESVERATROL;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC DRUG ADMINISTRATION; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG SCREENING; ESCAPE BEHAVIOR; LATENT PERIOD; LEARNING DISORDER; LOCOMOTION; MALE; MAZE TEST; MEMORY DISORDER; MENTAL CAPACITY; MOUSE; NONHUMAN; PASSIVE AVOIDANCE; TREATMENT DURATION;

EID: 84862222620     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/s1734-1140(12)70785-5     Document Type: Article

References (38)

1. Ader R, Weijnen JAWM, Maleman P: Retention of passive avoidance responses as a function of the intensity and duration of the electric shock. Psychonom Sci, 1972, 26, 125-132.
2. Barnes CA, Danysz W, Parsons CG: Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation spatial memory in awake, freely moving rats. Eur J Neurosci, 1996, 8, 565-571. (Pubitemid 26090761)
3. Baur JA, Sinclair DA: Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov, 2006, 5, 493-506. (Pubitemid 44136961)
4. Bertelli AA, Giovannini L, Giannessi D, Migliori M, Bernini W, Fregoni M, Bertelli A: Antiplatelet activity of synthetic natural resveratrol in red wine. Int J Tissue React, 1995, 17, 1-3.
5. Blokland A: Scopolamine-induced deficits in cognitive performance: A review of animal studies. Scopolamine Rev, 2005, 1-76.
6. Das DK, Sato M, Ray PS, Maulik G, Engelman RM, Bertelli AA, Bertelli A: Cardioprotection of red wine: Role of polyphenolic antioxidants. Drugs Exp Clin Res, 1999, 25, 115-120. (Pubitemid 29257603)
7. Gescher AJ, Steward WP: Relationship between mechanisms, bioavailibility, preclinical chemopreventive efficacy of resveratrol: a conundrum. Cancer Epidemiol Biomarkers Prev, 2003, 12, 953-957. (Pubitemid 37310248)
8. Giacobini E: Cholinergic foundations of Alzheimer's disease therapy. J Physiol Paris, 1998, 92, 283-287.
9. Giacobini E: Cholinesterases: new roles in brain function in Alzheimer's disease. Neurochem Res, 2003, 28, 15-22.
10. Goldberg DM, Yan J, Soleas GJ: Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem, 2003, 36, 79-87. (Pubitemid 36126394)
11. Han YS, Zheng WH, Bastianetto S, Chabot JG, Quirion R: Neuroprotective effects of resveratrol against β-amyloid induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C. Br J Pharmacol, 2004, 141, 997-1005. (Pubitemid 38510083)
12. Hsieh MT, Hsieh CL, Lin LW, Wu CR, Huang GS: Differential gene expression of scopolamine-treated rat hippocampus-application of cDNA microarray technology. Life Sci, 2003, 73, 1007-1016.
13. Itoh J, Nabeshima T, Kameyama T: Utility of elevated plus-maze for the evaluation of memory in mice; effects of nootropics, scopolamine and electroconvulsive shock. Psychopharmacology, 1990, 101, 27-33. (Pubitemid 20124737)
14. Jang JH, Surh YJ: Protective effects of resveratrol on β-amyloid-induced oxidative PC12 cell death. Free Radic Biol Med, 2003, 34, 1100-1110.
15. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH et al.: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 1997, 275, 218-220. (Pubitemid 127696281)
16. Jang M, Pezzuto JM: Cancer chemopreventive activity of resveratrol. Drugs Exp Clin Res, 1999, 25, 65-77. (Pubitemid 29257597)
17. Kim MJ, Choi SJ, Lim ST, Kim HK, Kim YJ, Yoon HG, Shin DH: Zeatin supplement improves scopolamine-induced memory impairment in mice. Biosci Biotechnol Biochem, 2008, 72, 577-581. (Pubitemid 351353676)
18. Konar A, Shah N, Singh R, Saxena N, Kaul SC, Wadhwa R, Thakur MK: Protective role of Ashwagandha leaf extract and its component Withanone on scopolamine-induced changes in the brain and brain-derived cells. PLoS ONE, 2011, 6, e27265. doi:10.1371/journal.pone.0027265.
19. Kopp P: Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the "French paradox". Eur J Endocrinol, 1998, 138, 619-620.
20. Kumar P, Padi SS, Naidu PS, Kumar A: Effect of resveratrol on 3-nitropropionic acid-induced biochemical behavioural changes: possible neuroprotective mechanisms. Behav Pharmacol, 2006, 17, 485-492. (Pubitemid 44325810)
21. Kwon SH, Kim HC, Lee SY, Jang CG: Loganin improves learning memory impairments induced by scopolamine in mice. Eur J Pharmacol, 2009, 619, 44-49.
22. LeDoux J E: Emotional memory systems in the brain. Behav Brain Res, 1993, 58, 69-79.
23. Lu R, Serrero G: Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J Cell Physiol, 1999, 179, 297-304. (Pubitemid 29203154)
24. Marambaud P, Zhao H, Davies P: Resveratrol promotes clearance of Alzheimer's disease amyloid-β peptides. J Biol Chem, 2005, 280, 37377-37382. (Pubitemid 41642343)
25. Mondadori C, Hengerer B, Ducret T, Borkowski J: Delayed emergence of effects of memory-enhancing drugs: implications for the dynamics of long-term memory. Proc Natl Acad Sci USA, 1994, 91, 2041-2045. (Pubitemid 24092038)
26. Morris R: Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods, 1984, 11, 47-60.
27. Patel MI, Gupta A, Dey CS: Potentiation of neuronal insulin signaling and glucose uptake by resveratrol: the involvement of AMPK. Pharmacol Rep, 2011, 63, 1162-1168.
28. Rizvi SI, Pandey KB: Activation of the erythrocyte plasma membrane redox system by resveratrol: a possible mechanism for antioxidant properties. Pharmacol Rep, 2010, 62, 726-732.
29. Savaskan E, Olivieri G, Meier F, Seifritz E, Wirz-Justice A, Müller-Spahn F: Red wine ingredient resveratrol protects from β-amyloid neurotoxicity. Gerontology, 2003, 49, 380-383. (Pubitemid 37465118)
30. Schmatz R, Mazzanti CM, Spanevello R, Stefanello N, Gutierres J, Corrȩa M, da Rosa MM et al.: Resveratrol prevents memory deficits and the increase in acetylcholinesterase activity in streptozotocin-induced diabetic rats. Eur J Pharmacol, 2009, 610, 2-8.
31. Sotheeswaran S, Pasupathy V: Distribution of resveratrol oligomers in plants. Phytochemistry, 1993, 32, 1083-1092.
32. Vingtdeux V, Giliberto L, Zhao H, Chandakkar P, Wu Q, Simon JE, Janle EM et al.: AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-peptide metabolism. J Biol Chem, 2010, 285, 9100-9113.
33. Vogel HG (Ed.): Drug effects on learning and memory. In: Drug discovery and evaluation: pharmacological assays. 2nd edn., Springer-Verlag, Berlin, Heidelberg, 2002, 619-620.
34. Walle T, Hsieh F, Delegge MH, Oatis JE Jr, Walle UK: High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos, 2004, 32, 1377-1382. (Pubitemid 39564557)
35. Wang Q, Xu J, Rottinghaus GE, Simonyi A, Lubahn D, Sun GY, Sun AY: Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res, 2002, 958, 439-447. (Pubitemid 35441199)
36. Wang Q, Yu S, Simonyi A, Rottinghaus G, Sun GY, Sun AY: Resveratrol protects against neurotoxicity induced by kainic acid. Neurochem Res, 2004, 29, 2105-2112. (Pubitemid 39663888)
37. Wenzel E, Somoza V: Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res, 2005, 49, 472-481. (Pubitemid 40780394)
38. Yu C, Shin YG, Chow A, Li Y, Kosmeder JW, Lee YS, Hirschelman WH et al.: Human, rat, mouse metabolism of resveratrol. Pharm Res, 2002, 19, 1907-1914. (Pubitemid 36016041)